Long-term Safety of Ketoconazole Foam, 2% in the Treatment of Seborrheic Dermatitis: Results of a Phase IV, Open-Label Study

January 2013 | Volume 12 | Issue 1 | Original Article | 1 | Copyright © January 2013


Zoe D. Draelos MD a, Steven R. Feldman MD PhD b, Victoria Butners BSc c, and Alessandra B. Alió Saenz MD c

aDepartment of Dermatology, Duke University School of Medicine, Durham, NC bDepartment of Dermatology, Wake Forest University, Winston-Salem, NC cStiefel, a GlaxoSmithKline (GSK) company, Research Triangle Park, NC

table 5
ing principal investigators: Texas: W. Abramovits, M. Jarratt, A. Menter, A. Moore, A. Pandya; California: E. Boh; North Carolina: Z. Draelos, S. Feldman; Alabama: B. Elewski; Rhode Island: E. Frankel; Massachusetts: A. Kimball; Virginia: D. Pariser; Florida: M. Rendon, D. Rodriguez, J. Spencer, S. Weiss; Oregon: P. Rich; Michigan: L. Stein Gold. The authors thank Alyson Bexfield PhD of Caudex Medical, Oxford, UK (supported by Stiefel, a GSK company, Research Triangle Park, NC), for assistance with preparing the initial draft of the manuscript, collating the authors’ comments, and assembling the tables.

DISCLOSURES

Dr. Draelos has received research support from Stiefel, a GSK company, including in relation to the study presented here. Dr. Feldman has received speaking, research, and/or consulting support from Stiefel/GSK, Astellas, Novartis, and Galderma Laboratories. Ms. Butners and Dr. Alió Saenz are employees of Stiefel, a GSK company.
This study was supported by Stiefel, a GSK company, Research Triangle Park, NC.

REFERENCES

  1. Berk T, Scheinfeld N. Seborrheic dermatitis. P T. 2010;35(6):348-352.
  2. Gupta AK, Bluhm R, Cooper EA, Summerbell RC, Batra R. Seborrheic dermatitis. Dermatol Clin. 2003;21(3):401-412.
  3. Zisova LG. Malassezia species and seborrheic dermatitis. Folia Med (Plovdiv). 2009;51(1):23-33.
  4. Franz TJ, Parsell DA, Halualani RM, Hannigan JF, Kalbach JP, Harkonen WS. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol. 1999;38(8):628-632.
  5. Franz TJ, Parsell DA, Myers JA, Hannigan JF. Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. Int J Dermatol. 2000;39(7):535-538.
  6. Feldman SR, Housman TS. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003;4(4):221-224.
  7. Extina Foam [package insert]. Research Triangle Park, NC: Stiefel Laboratories, Inc; 2007. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021738lbl.pdf. Accessed August 13, 2012.
  8. Elewski B, Ling MR, Phillips TJ. Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial. J Drugs Dermatol. 2006;5(7):646-650.
  9. Elewski BE, Abramovits W, Kempers S, et al. A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions. J Drugs Dermatol. 2007;6(10):1001-1008.
  10. Piérard-Franchimont C, Piérard GE, Arrese JE, De Doncker P. Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments. Dermatology. 2001;202(2):171-176.
  11. Jones-Caballero M, Pedrosa E, Peñas PF. Self-reported adherence to treatment and quality of life in mild to moderate acne. Dermatology. 2008;217(4):309-314.

AUTHOR CORRESPONDENCE

Zoe D. Draelos MDzdraelos@northstate.net
Close Menu